H.C. Wainwright lowered the firm’s price target on Fennec to $15 from $18 and keeps a Buy rating on the shares post the Q1 report. The analyst says the company’s product sales are slower than anticipated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
- Fennec Pharmaceuticals Sees Robust Q1 Growth
- Fennec reports Q1 EPS 41c, consensus 26c
- Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- FENC Upcoming Earnings Report: What to Expect?
- Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024